AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02082730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASARM
Description: The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
Study NCT03085745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
Study NCT00088894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00088894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00088894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00088894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00465647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
Study NCT03476369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90Mg Tablet
Description: Ticagrelor administered crushed vs non-crushed
Study NCT01649375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab 75 mg s.c.
Study NCT01649375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00568087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
Study NCT00568087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take oral placebo (identical matching placebo) during the study period.
Study NCT02804035 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sc2Wear Furosemide
Description: Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
Study NCT01649375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab 150 mg s.c.
Study NCT03940391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and midazolam
Description: Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
Study NCT03940391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
Study NCT04016077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 30 mg
Description: PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
Study NCT00820001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Treatment
Description: Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
Study NCT00820001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No-Booster
Description: All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
Study NCT00820001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
Study NCT00820001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: All cases assigned to this arm simply participated in all of the proposed routine assessments.
Study NCT01859507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
Study NCT02148120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
Study NCT02148120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
Study NCT02148120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04224597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: all participants will be determined by ultrasonography.
Study NCT02781168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of earmuffs
Description: The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
Study NCT02781168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of earmuffs
Description: The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
Study NCT04213768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral rectus plication
Description: The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
Study NCT04213768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral rectus Resection
Description: Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
Study NCT03090698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: intra-articular administration
Study NCT03090698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intra-articular administration
Study NCT01324648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-supported self-help and GP treatment as usual
Description: Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing.
Study NCT01324648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupported self-help and GP treatment as usual
Description: This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
Study NCT01324648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General practitioner treatment as usual
Description: This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
Study NCT03488498 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
Study NCT03328351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: 1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times.
Study NCT03328351 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Superficial soft tissue massage
Description: 1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times
Study NCT02711007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
Study NCT02106403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prototype disinfectant spray formulation
Description: 0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
Study NCT02106403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: 0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
Study NCT02106403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative control
Description: 0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
Study NCT03511157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: See Ischemic Preconditioning Experimental group description
Study NCT03511157 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: See Control group description
Study NCT01939639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal application, sodium chloride solution, 3 puffs per nostril
Study NCT01939639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU Oxytocin, intranasal application 45 min prior to the experiment
Study NCT01496846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IANB Articaine
Description: IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
Study NCT01496846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUP Articaine
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
Study NCT01496846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUP Lidocaine
Description: After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
Study NCT02128880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARRII
Description: CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
Study NCT02128880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CARRII Education
Description: CARRII Education provides information on women's health related to drinking and contraception in a static website format.
Study NCT04429724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test Covid-19
Description: Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
Study NCT02452450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Acid
Study NCT02452450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Lysine
Study NCT02452450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Study NCT02452450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Liquid Capsules
Study NCT02452450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02622893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic nephrectomy
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
Study NCT02622893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retroperitoneal laparoscopic nephrectomy
Description: After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
Study NCT04552106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x3/day
Description: 3 capsules 3 times daily for 28 days
Study NCT02008448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Study NCT02008448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Linear Lesion Ablation
Study NCT02008448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BT injection
Study NCT04091646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Foam 0.3%
Description: Roflumilast foam for topical application.
Study NCT04091646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Vehicle foam for topical application.
Study NCT02224911 — intervention group
Intervention type: DEVICE
Intervention: Laser Interstitial Thermal Therapy
Study NCT02606591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalograph
Description: EEG performed at beginning and end of school year.
Study NCT04552106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x2/day
Description: 3 capsules 2 times daily for 28 days
Study NCT04552106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 caps x3/day
Description: 2 capsules 3 times daily for 28 days
Study NCT03675282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
Study NCT04552106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 caps x2/day
Description: 2 capsules 2 times daily for 28 days
Study NCT03675282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
Study NCT04552106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x1/day
Description: 3 capsules 1 times daily for 28 days
Study NCT01227863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXINOM®
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
Study NCT02606591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
Study NCT02606591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Sample
Description: Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral repeating dose
Study NCT00539838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Description: Oral repeating dose
Study NCT03738826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
Study NCT03331978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rise - Treatment Education
Description: Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.